Subscribe

Shitanshu Uppal

GOG 261: Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Carcinosarcoma

Carboplatin/Taxol is not inferior to Ifos/Taxol in terms of OS and significantly increases PFS, making it a new standard treatment for carcinosarcoma

Publications Update # 53

HER-2 testing in gynecologic cancers, prognostic role of ITCs in low-grade endometrial cancer, primary cytoreduction in ovarian cancer.

Climate - GYOEDU.org

Read more on how Stripe helps GYOEDU contribute towards carbon

Publications Update # 52

Becoming G.O.A.T by adopting a goat's mentality, 3+3 clinical trial design, vulvar cancer groin node management and the risk of ovarian metastasis in endometrial cancer patients less than 50

Publications Update # 51

CALLA trial, Keynote-A18, myoinvasive or non-myoinvasive p53 abn stage 1A endometrial cancer and the effect of isolation on humans

KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer

Pembrolizumab combined with chemoradiotherapy and then continued post-chemoradiotherapy demonstrates significant improvements in progression-free survival and OS compared to chemoradiotherapy alone

CALLA: Durvalumab versus placebo with chemoradiotherapy

Durvalumab concurrent with chemoradiotherapy was well tolerated but did not significantly improve progression-free survival compared to placebo in a biomarker-unselected all-comers population for locally advanced cervical cancer

SCORPION: Primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer

Neoadjuvant chemotherapy and primary debulking surgery showed similar efficacy in terms of progression-free and overall survival. However, neoadjuvant chemotherapy resulted in significantly lower rates of post-operative complications, suggesting a different toxicity profile

GOG 249: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer

The study did not demonstrate superiority or equivalence due to similar outcomes in both arms. The higher incidence of pelvic/para-aortic nodal failures in the VCB/C arm suggests the importance of pelvic RT in preventing regional recurrences.

KEYNOTE 775: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

Lenvatinib plus pembrolizumab significantly improves progression-free and overall survival compared to chemotherapy among patients with advanced endometrial cancer.